$THC

Foo Lisa Y sold $2.6M of THC

Foo Lisa Y (EVP, Chief Operating Officer) sold 10,000 shares of TENET HEALTHCARE CORP (THC) at $258.03 ($2.58M total) on 2026-07-29.

Original reporting
SEC EDGAR · Foo Lisa Y
Published Aug 1, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 1, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest fact is the specific sale details: 10,000 shares at $258.03, total value $2.58M, with holdings after sale of 32,053 shares, and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 6/10Novelty 4/10Timing: Form 4 filed 2026-07-31, transaction dated 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare, reporting an open-market sale by the COO.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare COO sold 10,000 shares in an open-market transaction at $258.03 on 2026-07-29, per Form 4 filed 2026-07-31.

Expected impact

Likely limited near-term impact; treat as low-signal unless paired with other disclosures or unusual volume.

Evidence & confidence

The filing discloses transaction size, price, and holdings, but provides no earnings, guidance, investigation, or deal catalyst. Insider sales are common and often non-informational, though the absence of a 10b5-1 plan slightly increases interpretive uncertainty.

Market effects

No clear sector read-through from a single insider sale at one healthcare services company.

None indicated.

None indicated.

Counterpoint

The lack of a 10b5-1 plan could reflect discretionary selling ahead of perceived risk, so some traders may front-run downside if they treat insider behavior as a leading indicator.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider transaction disclosure.

  • Foo Lisa Y

    EVP, Chief Operating Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

$THCMedAI 8/10

Tenet Healthcare at Wells Fargo conference: high-acuity push deepens

Tenet Healthcare (THC) presented at the Wells Fargo Healthcare Conference, outlining a strategy focused on high-acuity care, capital spending, and cost control. The company raised full-year guidance, citing volume growth and cost discipline. Shares are near their 52-week high at $268.82, up over 30% year-to-date. Tenet expects continued pressure in some payer channels and near-term earnings drag from Conifer's transition. Management plans to invest in complex procedures and maintain capital spen